CPL-01, to the Non-opioid treatment of postoperative pain, Garner’s publication of clinical dataa in abdominoplasty and presentation of preclinical data in bone and soft tissue models supportive Pharmacokinetics and safety
SAN DIEGO, October 26, 2022 /PRNewswire/ — Cali Biosciences Co., Ltd. (hereinafter referred to as “Cali Biosciences”), a biopharmaceutical company focused on the discovery and development of innovative medicines, announced two major milestones for CPL-01, its long-acting ropivacaine known for postoperative analgesia and opioid elimination/ -Reduction:
- Publication of “CPL-01, an Investigational Long-Acting Ropivacaine, Exhibits Extended-Release Properties after Mini-abdominoplasty” in a peer-reviewed medical journal, Japan Journal of Medicine.
- Preclinical data presented at the American Association of Pharmaceutical Sciences’ prestigious annual Pharma 360 meeting, confirming the tolerability and durability of CPL-01 in both soft tissue surgery and bone tissue surgery.
CPL-01 is an extended-release injectable version of Naropin® (ropivacaine hydrochloride) developed by Cali Biosciences to manage postoperative surgical pain and reduce or eliminate the need for opioids. The publication in Japan The Journal of Medicine confirmed that the study demonstrated long-lasting pain control and opioid reduction while further supporting the safety and efficacy of CPL-01. Hanghang “Tommy” Xu, Calis Head of Clinical Research for Asiastated, “The advantages of ropivacaine over bupivacaine are well established in the literature, so the advantages of ropivacaine as the anesthetic of choice in a long-acting analgesic are self-evident.” DR. Ira Gottliebthe PI of the study and co-author of the manuscript, agreed: “While long-acting bupivacaine has entered the market in the last decade, this is the most advanced long-acting ropivacaine and could be a game changer.” The article itself is about the following reference available: Hanghang Tommy Xu, Lee ChenPJ…
